Selank
ProtocolScheduling Selank alongside existing protocols, training, and lifestyle inputs requires understanding the compound's pharmacokinetic constraints and the cycle calendar. A Russian-developed heptapeptide derived from tuftsin — anxiolytic without sedation, supported by clinical trial data in generalised anxiety disorder. Daily timing relative to meals and training, weekly cycle structure, and integration with stack components on independent pathways are the three layers of the protocol calendar developed below.
Key Takeaways
Scheduling lens: Selank's CNS effect lasts hours; plasma short half-life via intranasal/subq places it in the multi-daily-dosing bucket. Mechanism: Modulates GABA-A receptor systems indirectly. Cycle structure: 8-12 weeks on, 4 weeks off; the off-period is functionally required for receptor reset. Stack scheduling: add one compound at a time with 2 weeks of isolated dosing before layering. Schedule-compatible stack partners: BPC-157, TB-500, Ipamorelin.
Modulates GABA-A receptor systems indirectly. Increases serotonin metabolism via enkephalinase inhibition. Influences IL-6, BDNF, and TNF-α. The result is anxiolysis without the sedation, dependence, or motor impairment of benzodiazepines. The scheduling implications cascade from this mechanism: receptor occupancy curves dictate daily timing, downregulation kinetics dictate cycle length, route compatibility dictates stack scheduling. The subsections address each in turn for Selank.
Cycle length and off-cycle planning
Standard Selank cycle length is 8–12 weeks for most users, with off-cycle periods of 4–6 weeks calibrated to allow receptor sensitivity to recover and any cumulative downregulation to resolve. The off-cycle is not optional in well-designed protocols; it is the period during which the dose response is reset for the next cycle.
Daily and weekly timing
Selank with a CNS effect lasts hours; plasma short half-life pharmacokinetic profile sits in the multiple-daily-dosing bucket. The schedule is best built around either Daily for 2-4 week courses, with consistency mattering more than the absolute clock time of any single dose.
Travel, schedule shifts, and continuity
Maintaining cycle continuity through travel, time-zone shifts, and irregular schedules is one of the practical considerations for any Selank protocol. Cold-chain requirements (where applicable), customs considerations for international travel, and adjustment for time-zone shifts within a 24–48 hour window are the main operational issues. For most Selank schedules a ±8-hour timing shift has no clinical effect; longer shifts warrant minor schedule adjustment.
The most-asked scheduling question for Selank in weekly timing is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
Schedule design for Selank in cycle design starts from pharmacokinetic constraints: less frequent dosing for long half-life compounds. The cycle length and off-period are then layered on top of the daily schedule.
For maintenance phase scheduling, Selank is best run in 8–12 week cycles with 4 week off-periods. Daily timing within the cycle is calibrated to pharmacokinetics; weekly timing is calibrated to training and lifestyle constraints. The schedule is the protocol.
The most-asked scheduling question for Selank in off-time is when to time doses relative to meals and training. The general principle: fasted dosing for compounds engaging the GH axis or AMPK; meal-paired dosing for incretins; flexibility for compounds whose pharmacokinetics permit it.
| Goal | Route | Dose | Cycle |
|---|---|---|---|
| Standard protocol | Intranasal | 300 mcg per spray; 2-3 sprays daily | 8–12 weeks on / 4 weeks off |
| Conservative starter | Intranasal | 180 mcg per spray; 2-3 sprays daily | 4–6 weeks initial cycle |
| Protocol focus | Intranasal | 300 mcg per spray; 2-3 sprays daily | Daily for 2-4 week courses |
| Maintenance phase | Intranasal | 210 mcg per spray; 2-3 sprays daily | Ongoing with periodic pauses |
Dose timing for Selank is important relative to food and training given the short half-life. Consistency through the cycle is more important than the precise clock time of individual doses.
Selank stacks well with compounds on complementary pathways. The pairings below are the conventional combinations from protocol designers.
- Selank + BPC-157: Upregulates VEGFR2 to promote angiogenesis and activates the FAK-paxillin pathway for accelerated tissue repair. Pairs naturally with Selank's mechanism in protocol / scheduling / cycling protocols.
- Selank + TB-500: Binds G-actin monomers and prevents their incorporation into F-actin filaments, regulating the cellular actin pool. Pairs naturally with Selank's mechanism in protocol / scheduling / cycling protocols.
- Selank + Ipamorelin: Highly selective GHSR1a agonist. Pairs naturally with Selank's mechanism in protocol / scheduling / cycling protocols.
- Selank + CJC-1295 without DAC (Mod GRF 1-29): Same GHRH-receptor agonism as DAC variant. Pairs naturally with Selank's mechanism in protocol / scheduling / cycling protocols.
Excellent. No reported dependence. Mild nasal irritation possible.
Lens-specific safety considerations for protocol / scheduling / cycling use of Selank: Excellent. No reported dependence. Mild nasal irritation possible. Additional protocol / scheduling / cycling monitoring at baseline and 6–8 week follow-up is appropriate.
| Compound | Profile | Onset | Best For |
|---|---|---|---|
| Selank | Tuftsin-derived heptapeptide anxiolytic | CNS effect lasts hours; plasma short | Protocol |
| BPC-157 | Stable gastric pentadecapeptide | ~4 hr (oral) | Accelerated tendon, ligament, and gut tissue repair via VEGFR2-driven angiogenesis and FAK-paxillin signalling |
| TB-500 | Synthetic thymosin β4 fragment | ~2-3 days | A 17-amino-acid synthetic fragment of thymosin β4 with actin-sequestering activity — drives cell migration, tissue repair, and broad regenerative effects |
| Ipamorelin | Selective GHRP / ghrelin mimetic | ~2 hr | The most selective ghrelin-receptor agonist among the GHRPs — stimulates GH release with minimal effect on cortisol, prolactin, or appetite |
| GHK-Cu | Tripeptide-copper complex | ~30 min plasma | A naturally occurring tripeptide-copper complex that declines with age and is studied for its broad effects on wound healing, skin remodelling, and gene expression |
Best practice for re-cycling?
What if I miss a dose?
Can I shift my schedule with travel?
When to integrate Selank into an existing stack?
Is Selank safe during pregnancy or breastfeeding?
How should Selank be stored and reconstituted?
Start a Selank Protocol
Alukard provides physician-supervised peptide protocols with GMP-certified Selank and GMP-certified compounds with personalised cycle design.
Get ProtocolQuick Facts
- Molecular weight
- 751 Da
- Sequence length
- 7 aa
- Half-life
- CNS effect lasts hours; plasma short
- WADA
- Not on prohibited list
- FDA
- Unapproved (approved in Russia)
- Research
- Russian clinical trials in GAD
Stack Partners
All protocol / scheduling / cycling applications described on this page are derived from preclinical research, animal models, and limited human case data. None of these uses are FDA-approved indications for Selank unless otherwise noted. Always work with a physician familiar with peptide therapeutics before beginning a protocol.
Start Your Protocol / Scheduling / Cycling Protocol for Selank
Alukard provides physician-supervised peptide protocols with GMP-certified compounds with personalised cycle design.
HIPAA Compliant · GMP Certified · Physician Supervised